Abstract:Objectives: Non-invasive prenatal testing (NIPT) has been widely used in recent years. According to clinical experience from all hospitals providing prenatal screening services in Beijing, we explored the feasibility of using NIPT for the analysis of common foetal aneuploidies among pregnancies. Methods: In total, 68,763 maternal blood samples were collected from January 2020 to December 2020 at the Beijing prenatal diagnosis agency. Cases with positive screening results by NIPT detection were validated using prenatal diagnosis. Results: In total, 920 cases had a high-risk NIPT result, and 755 cases were shown to be truly positive by a chromosome karyotyping analysis; the prenatal diagnosis rate was 82.07% (755/920). Of the920 cases, there were 164 cases of T21, 70 cases of T18, 38 cases of T13, 360 cases of SCAs and 288 cases of other chromosomal abnormalities. The positive rates of T21, T18, T13, and SCAs were 0.24% (164/68,763), 0.10% (70/68,763), 0.06% (38/68,763) and 0.52% (360/68,763), respectively. The sensitivity and specificity were 98.17% and 99.92% for T21, 96.15% and 99.93% for T18, and 100% and 99.95% for T13, respectively. The PPVs of T21,T18,T13 and SCAs were65.24% (107/164), 35.71% (25/70), 18.42% (7/38) and 31.39% (113/360), respectively. For all indications, there were more higher T21/18/13 in the high-risk group than in the low-risk group (comprising only cases of voluntary request), with a positive rate of 0.46% vs. 0.27% ( p < 0.001), sensitivity of 99.16% vs. 91.30% ( p = 0.02) and PPV of 56.73%vs.32.81% ( p = 0.001), but there was no significant difference in specificity between the groups ( p = 0.71). The detection indication with the highest PPV (100%) by NIPT was ultrasound structural abnormalities and ultrasound soft marker abnormalities for T21 and ultrasound structural abnormalities and NT thickening for T18 and T13. The PPVs of different clinical indications of T21 ( p = 0.002), T13 ( p = 0.04) and SACs ( p = 0.02) were statistically significant. Conclusion: The high specificity, efficiency and safety (non-invasiveness) of NIPT can effectively improve the detection rate of common chromosomal aneuploidy, thereby reducing the occurrence of birth defects. We should encourage pregnant women with NIPT-high-risk results to undergo a prenatal diagnosis to determine whether the foetus has chromosomal abnormalities. More importantly, the screening efficiency of NIPT in the low-risk group was significantly lower than that in the high-risk group. Therefore, the use of NIPT in low-risk groups should be fully promoted, and socioeconomic benefits should be considered.

Analysis of Prenatal Serological Screening of 116 Pregnant Women with Trisomy 21 Syndrome Fetus

Predictive Significance of Risk Value in Prenatal Screening for Fetal Trisomy 18

Clinical application of noninvasive prenatal testing for the detection of trisomies 21, 18, and 13: a hospital experience.

Noninvasive Prenatal Testing of Trisomies 21 and 18 by Massively Parallel Sequencing of Maternal Plasma DNA in Twin Pregnancies.

Meta-analysis of Prenatal Screening for Trisomy 21 Using Nuchal Translucency Measurement with Serum Markers

Detection of trisomies 13, 18 and 21 using non-invasive prenatal testing

[Analysis of the results of chromosomal trisomies 21, 18 and 13 screening among 40 628 women by non-invasive prenatal testing]

Discordant performances of non-invasive prenatal testing for foetal trisomy 21 screening in subgroups of pregnancies

Non-invasive prenatal testing for the detection of trisomy 13, 18, and 21 and sex chromosome aneuploidies in 68,763 cases

Non-invasive Prenatal Testing for the Detection of Trisomies 21, 18, and 13 in Pregnant Women with Various Clinical Indications: A Multicenter Observational Study of 1,854,148 Women in China

Maternal Prenatal Screening Programs That Predict Trisomy 21, Trisomy 18, and Neural Tube Defects in Offspring

The value of nipt combined with serum cell-free dna, estriol, afp, and -hcg levels in the recognition of trisomy 21 and 18 in the second trimester

Performance of Non-Invasive Prenatal Testing for Trisomies 21 and 18 in Twin Pregnancies.

Efficiency of Non-invasive Prenatal Screening in Pregnant Women at Advanced Maternal Age

Clinical Efficiency of Non-invasive Prenatal Screening for Common Trisomies in Low-Risk and Twin Pregnancies

Clinical performance of non-invasive prenatal served as a first-tier screening test for trisomy 21, 18, 13 and sex chromosome aneuploidy in a pilot city in China

[Prenatal diagnosis and outcome of pregnancy for women with high risks by screening of fetal free DNA from peripheral blood samples]

Non-invasive Prenatal Testing for Trisomies 21, 18 and 13: Clinical Experience from 146,958 Pregnancies.

A Risk Model for Predicting Fetuses with Trisomy 21 Using Alpha-Fetoprotein Variants L2 Combined with Maternal Serum Biomarkers in Early Pregnancy

Association of maternal risk factors with fetal aneuploidy and the accuracy of prenatal aneuploidy screening: a correlation analysis based on 12,186 karyotype reports

Analysis of 17,428 Pregnant Women Undergoing Non-Invasive Prenatal Testing for Fetal Chromosome in Northeast China